share_log

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win

這些股票在Biogen-Eisai出人意料的阿爾茨海默氏症試驗獲勝後受到關注
Benzinga Real-time News ·  2022/09/28 16:10  · 市場
One of the most-watched Alzheimer's therapies in the clinic, Biogen(BIIB.US) Inc-Eisai Limited's (OTC:ESALY) experimental lecanemab reduced clinical decline on the scale by 27% compared to the placebo at 18 months in early Alzheimer's. In July 2022, the FDA accepted the marketing application for lecanemab under the accelerated approval pathway and granted a Priority Review. The PDUFA date is Jan. 6, 2023. Several stocks related to Alzheimer's programs are gaining. SVB Leerink said these positive results would reinvigorate the Alzheimer's space.
這是臨牀上最受關注的阿爾茨海默氏症療法之一,Biogen(BIIB.US)INC-衞材有限公司的(場外交易代碼:ESALY)在18個月的早期阿爾茨海默病患者中,試驗性lecanemab與安慰劑相比,減少了27%的臨牀下降。 2022年7月,FDA在加速審批路徑下接受了lecanemab的上市申請,並批准了優先審查。PDUFA的日期是2023年1月6日。 與阿爾茨海默氏症項目相關的幾隻股票正在上漲。SVB Leerink表示,這些積極的結果將使阿爾茨海默氏症領域重新煥發活力。
Eli Lilly and Co(LLY.US) - Market cap: $317 billion.
禮來(LLY美國)-市值:3170億美元。
Positive readthrough is expected from its...
預計2023...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論